GUILLERMO
LÓPEZ VIVANCO
Chercheur jusqu' 2022
Hospital Universitario de la Princesa
Madrid, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario de la Princesa (8)
2023
2021
-
First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met
European Journal of Cancer, Vol. 159, pp. 174-181
-
Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
Cancer Chemotherapy and Pharmacology, Vol. 87, Núm. 4, pp. 543-553
2017
-
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
Journal of the National Cancer Institute, Vol. 109, Núm. 9
2016
-
Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: A retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study
Melanoma Research, Vol. 26, Núm. 3, pp. 278-283
2015
-
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
Scientific Reports, Vol. 5
2012
2009
-
Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression
PLoS ONE, Vol. 4, Núm. 5